Effect of Fetuin A in Hemodialysis Patients
- Conditions
- HemodialysisMalnutrition
- Registration Number
- NCT00309426
- Lead Sponsor
- University of Shizuoka
- Brief Summary
The purpose of this study is to examined the effect of fetuin A on atherosclerosis and prognosis in hemodialysis patients.
- Detailed Description
Fetuin A is known to be a potent inhibitor of ectopic calcification in plasma, and the concentration of fetuin A is closely associated with protein nutritional status. The purpose of this study is to examine whether the plasma concentration of fetuin A is associated with atherosclerosis and 5-year prognosis in hemodialysis patients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Hemodialysis for at least 6 months
Exclusion Criteria
- Disabled patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link fetuin A to atherosclerosis in hemodialysis patients?
How does fetuin A concentration compare to standard-of-care biomarkers in predicting prognosis for hemodialysis patients?
What biomarkers correlate with fetuin A levels in malnourished hemodialysis patients?
Are there adverse events associated with low fetuin A levels in long-term hemodialysis patients?
What combination therapies with fetuin A analogs are being explored for managing vascular calcification in ESRD?
Trial Locations
- Locations (1)
Maruyama Hospital
🇯🇵Hamamatsu, Shizuoka, Japan
Maruyama Hospital🇯🇵Hamamatsu, Shizuoka, Japan